Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Shares Outstanding (Diluted Average) (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $57.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 23.81% year-over-year to $57.3 million, compared with a TTM value of $57.3 million through Dec 2025, up 23.81%, and an annual FY2025 reading of $57.3 million, up 23.81% over the prior year.
  • Shares Outstanding (Diluted Average) was $57.3 million for Q4 2025 at Zevra Therapeutics, up from $56.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $57.3 million in Q4 2025 and bottomed at $41.9 million in Q2 2024.